Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis - Jauslin, Petra; Kulkarni, Pooja; Li, Hanbin; Vatakuti, Suresh; Hussain, Azher; Wenning, Larissa; Kerbusch, Thomas (Clinical pharmacokinetics, 2019)
Keywords: Creatinine; Cytokines; Datasets; Ethnicity; Internal Medicine; Medicine; Medicine & Public Health; Monoclonal antibodies; NCT; NCT01225731; NCT01722331; NCT01729754; Original Research Article; Patient satisfaction; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Population; Psoriasis